文献速递神经MR

基于人工智能的胶质母细胞瘤脑肿瘤反应自动评估的开发与评价

Development and Evaluation of Automated Artificial Intelligence-Based Brain Tumor Response Assessment in Patients with Glioblastoma.
PubMed 文献 · AJNR Am J Neuroradiol · 2025-05-02

本研究回顾性分析634例胶质母细胞瘤患者、3403次脑MRI检查及对应BT-RADS评估,开发基于自动容积肿瘤分割的AI-VTRA算法;AI-VTRA与放射科医生评估呈中度一致(F1=0.587-0.755),但生存分层略差于人工评估。

要点

  • AI-VTRA按BT-RADS标准与放射科医生评估呈中度一致(F1=0.587-0.755)。
  • 人工评估为影像进展等效RANO进展的患者,固定时间点总生存统计学上差于AI评估者(log-rank P=.007)。
  • Cox比例风险模型显示AI评估在总生存预测上存在劣势(P=.012)。

核心结论

  • AI-VTRA遵循BT-RADS标准,在复现人工反应评估方面呈中度一致,按总生存的分层略差。

研究设计与样本

  • 回顾性分析单中心5年(2017-2021)634例胶质母细胞瘤患者,平均年龄56±13岁,男性372/634(59%)、女性262/634(41%);数据含3403次脑MRI检查及对应放射科医生BT-RADS评估,开发基于自动容积肿瘤分割的AI-VTRA算法,以BT-RADS为参考标准计算一致性,并行固定时间点生存分析。

诊断标准与关键数值

  • 以放射科医生BT-RADS为参考标准,AI-VTRA在所有BT-RADS类别与人工评估的F1为0.587-0.755(中度一致)。

临床应用与阅片要点

  • AI-VTRA按BT-RADS标准可中度复现放射科医生的脑肿瘤反应评估,但Cox比例风险模型显示AI评估在总生存预测上存在劣势(P=.012)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

This project aimed to develop and evaluate an automated, AI-based, volumetric brain tumor MRI response assessment algorithm on a large cohort of patients treated at a high-volume brain tumor center. We retrospectively analyzed data from 634 patients treated for glioblastoma at a single brain tumor center over a 5-year period (2017-2021). The mean age was 56 ± 13 years. 372/634 (59%) patients were male, and 262/634 (41%) patients were female. Study data consisted of 3,403 brain MRI exams and corresponding standardized, radiologist-based brain tumor response assessments (BT-RADS). An artificial intelligence (AI)-based brain tumor response assessment (AI-VTRA) algorithm was developed using automated, volumetric tumor segmentation. AI-VTRA results were evaluated for agreement with radiologist-based response assessments and ability to stratify patients by overall survival. Metrics were computed to assess the agreement using BT-RADS as the ground-truth, fixed-time point survival analysis was conducted to evaluate the survival stratification, and associated P-values were calculated. For all BT-RADS categories, AI-VTRA showed moderate agreement with radiologist response assessments (F1 = 0.587-0.755). Kaplan-Meier survival analysis revealed statistically worse overall fixed time point survival for patients assessed as image worsening equivalent to RANO progression by human alone compared to by AI alone (log-rank P = .007). Cox proportional hazard model analysis showed a disadvantage to AI-based assessments for overall survival prediction (P = .012). In summary, our proposed AI-VTRA, following BT-RADS criteria, yielded moderate agreement for replicating human response assessments and slightly worse stratification by overall survival.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Zhang J, LaBella D, Zhang D, et al. Development and Evaluation of Automated Artificial Intelligence-Based Brain Tumor Response Assessment in Patients with Glioblastoma. AJNR Am J Neuroradiol. 2025. PMID: 39542725. doi:10.3174/ajnr.A8580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。